Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine
Psychiatry Investigation
;
: 422-424, 2012.
Article
in English
| WPRIM
| ID: wpr-14285
ABSTRACT
I report here an elderly woman receiving perphenazine together with terbinafine. After 1 week of terbinafine treatment she experienced extrapyramidal symptoms and, in particular, akathisia. Her symptoms did not disappear for 6 weeks, and so at 2 weeks prior to this most recent admission she had stopped taking terbinafine. However, these symptoms persisted for 3 weeks after discontinuing terbinafine. It is well known that terbinafine inhibits CYP2D6 and that perphenazine is metabolized mainly by CYP2D6. Thus, when terbinafine and perphenazine are coadministrated, the subsequent increase in the concentration of perphenazine may induce extrapyramidal symptoms. Thus, terbinafine therapy may be associated with the induction and persistence of extrapyramidal symptoms, including akathisia. This case report emphasizes the importance of monitoring drug-drug interactions in patients undergoing terbinafine and perphenazine therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Perphenazine
/
Psychomotor Agitation
/
Cytochrome P-450 CYP2D6
/
Naphthalenes
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
Psychiatry Investigation
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS